Aprea Therapeutics Inc (APRE NASDAQ) stock market data APIs
$0.6744
0.04(5.9%)
as of February 3, 2026
Try our APIs with
free plan!
Aprea Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Prev. Close
0.6744
Open
0.7117
High
0.7616
Low
0.6493
52 wk Range
0.548-4.65
Market Cap
5 251 K
Shares Outstanding
6 994 K
Revenue
488 K
EPS
-0.47
Beta
1.61
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aprea Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aprea Therapeutics Inc data using free add-ons & libraries
Get Aprea Therapeutics Inc Fundamental Data
Aprea Therapeutics Inc Fundamental data includes:
- Net Revenue: 488 K
- EBITDA: -13 795 074
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.28
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aprea Therapeutics Inc News
New
New Strong Sell Stocks for January 19th
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Aprea Therapeutics APRE is a biopharmaceutical company which is focused on developing and commercializing novel cancer thera...
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treat...
Aprea Therapeutics GAAP EPS of -$0.47, revenue of $1.84M
* Aprea Therapeutics press release [https://seekingalpha.com/pr/20303880-aprea-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a-clinical] (APRE [https://seekingalpha.com/symb...
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in pat...
Get Aprea Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
